Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Microbiota 7 - June 2019
  3. Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 7 - June 2019
  3. Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition
Gastroenterology

Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition

Crohn's disease

Commented articles - Children's section

By Pr. Emmanuel Mas
Gastroenterology and Nutrition Department, Children’s Hospital, Toulouse, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

Photo : Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition

About this article

Created 25 August 2021
Updated 04 November 2021

Commentary on the original publication by Svolos et al. (Gastroenterology 2019)

Exclusive enteral nutrition (EEN) is the only established dietary treatment in Crohn’s disease (CD), but its acceptability is limited. There is a need for new dietary treatments for CD.

The effects of a personalized diet (CD-TREAT), based on the composition of EEN, were evaluated by analysing the intestinal microbiota, inflammation and clinical response in rats, in healthy adults, and in children with relapsing CD.

Ultimately, it was shown that CD-TREAT replicates EEN changes in the gut microbiota, decreases gut inflammation, is well tolerated and is potentially effective in patients with active CD.[1]

What do we know about this subject?

Exclusive enteral nutrition (EEN) is an effective treatment of Crohn’s disease with ileus involvement, achieving good results (mucosal healing in 80% of cases) that are superior to those obtained with corticotherapy. However, the main obstacle is the acceptability of receiving, for at least 8 weeks, exclusive enteral nutrition. EEN is delivered by nasogastric tube or, as for Modulen IBD®, by the oral route. The mechanism of action of EEN is not fully understood but several studies suggest that it acts by modulating the intestinal microbiota.

What are the main insights from this study? 

This study aimed to determine whether an ordinary diet (CD-TREAT), i.e. oral intake of ordinary foods but based on a nutrient composition similar to that of Modulen IBD®, could be effective in Crohn’s disease. The proportion of carbohydrate was decreased and that of protein increased. A multivitamin tablet provided the micronutrients from EEN. A crossover study was conducted in 25 healthy adult volunteers who received CD-TREAT or EEN for one week each, with a washout period in between. CD-TREAT was easier to follow and more satiating than EEN. Microbiota richness and alpha diversity were not altered by these diets. However, the relative abundance of 58 (49.3%) and 38 (32.3%) bacterial genera changed significantly after EEN and CD-TREAT, respectively, of which 28 changed in the same direction. There were changes in the concentrations of different metabolites (some short chain fatty acids – acetate, propionate and butyrate significantly decreased after EEN and CD-TREAT) and faecal pH increased by about 1 unit. 

5 groups of rats, HLA B27 (inflammatory) and B7 (non-inflammatory): B27-EEN, B27-CD-TREAT, B27-CONTROL, B7-EEN and B7-CONTROL. EEN and CD-TREAT decreased ileal inflammation (Figure 1A), with lower expression of IL-6 in the B27- CD-TREAT group compared to the B27- CONTROL group (p = 0.036). After the 4-week intervention, bacterial diversity was higher in cecum (Figure 1B) and in feces in the B27-CD-TREAT and B27-EEN groups versus B27-CONTROL. Both diets caused changes in faecal concentrations of some short chain fatty acids.

Lastly, 5 children to mild to moderate Crohn’s disease, (wPCDAI score 22.5 to 42.5) were treated with CD-TREAT for 8 weeks. One child discontinued after 9 days because of symptom exacerbation. After 4 weeks, 3 children (60%) had a clinical response (wPCDAI score change > 17.5) and 2 children (40%) were in clinical remission (wPCDAI score < 12.5). After 8 weeks, 80% of children (4 of 5) had a clinical response and 60% (3 of 5) were in clinical remission. The mean baseline level of faecal calprotectin of 1,960 mg/kg decreased by 53% and 55%, respectively, after 4 and 8 weeks (Figure 2). Calprotectin decreased to normal in only one child.

Key points

  • A suitable oral diet could be as effective as exclusive enteral nutrition in Crohn’s disease.

  • Its effect on the intestinal microbiota mimics that of exclusive enteral nutrition.

  • It offers an alternative to exclusive enteral nutrition which is poorly accepted by patients.

Image

What are the consequences in practice? 

This study shows that this diet is more feasible when given orally and that it mimics the effects of EEN with Modulen IBD® on the gut microbiota. CD-TREAT also improves clinical signs and reduces gut inflammation.

Conclusion

This study provides proof-ofconcept that a novel and better tolerated dietary treatment could be effective in Crohn’s disease. These findings need to be confirmed in large, controlled, randomized clinical trials.

Sources

1 Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology 2019; 156: 1354-67.

Tags
Gastroenterology Pediatrics Diet

en_view en_sources

    Focus
    Microbiota 7 - June 2019
    • Overview
      • Digestive cancers and intestinal microbiota: from oncogenesis to response to treatment
    • Commented articles
      • Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant
      • Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition
    • Congress review
      • Review of the main contributions related to the intestinal microbiota
      • Gut Microbiota for Health World Summit 2019
    • Press review
      • The impact of the parents’ microbiome on the descendants health
      • Esophageal microbiome cause or consequence esophageal diseases
    Created 25 August 2021
    Updated 04 November 2021

    About this article

    To know more about this topic.

    Main topic

    Crohn's disease

    Content type

    Commented article
    Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant
    Review of the main contributions related to the intestinal microbiota
    Focus

    Microbiota 7 - June 2019

    Overview

    Digestive cancers and intestinal microbiota: from oncogenesis to response to treatment

    Commented articles

    Reconstitution of the gut microbiota of antibiotic-treated patients by autologous faecal microbiota transplant Treatment of active crohn’s disease with an ordinary foodbased diet that replicates exclusive enteral nutrition

    Congress review

    Review of the main contributions related to the intestinal microbiota Gut Microbiota for Health World Summit 2019

    Press review

    The impact of the parents’ microbiome on the descendants health Esophageal microbiome cause or consequence esophageal diseases

    Continue reading

    News
    22.11.2021

    Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term?

    Read the article
    WMD_Foundation KOL Mexico 2019
    10.06.2022

    Pr. Moisés Alvarez (Mexican winner 2019): Microbiota & colorectal cancer

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article
    WMD_Foundation KOL USA 2021
    16.06.2022

    Dr. Queen (USA winner 2020): Microbiota & colorectal cancer

    Read the article
    WMD_Foundation KOL USA 2022
    16.06.2022

    Dr. Brown (USA winner 2021): Microbiota & respiratory syncitial virus infection

    Read the article
    31.05.2022

    Pr. Maslennikov (Russian winner 2019): Probiotics & cirrhosis

    Read the article
    WMD_Foundation KOL Russia 2020
    15.06.2022

    Pr. Shifrin (Russian winner 2020): Gut microbiota & antibiotics

    Read the article
    WMD_Foundation KOL Russia 2021
    15.06.2022

    Pr. Volynets (Russian winner 2021): Gut microbiota & hepatobiliary chronic diseases

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Postménopause : l'action bénéfique de l'estradiol sur le microbiote vaginal
    22.06.2022

    Postmenopause: the beneficial action of estradiol on the vaginal microbiota

    Read the article
    WMD_Foundation KOL USA 2018
    17.06.2022

    Dr. Yang (USA winner 2018): Gut microbiota & gut brain axis

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo